5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

The workload at pCPA appears to have stabilized over 2019

November 14, 2019
-
Market Access News
-
Posted by MORSE - 3 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): October 2019 Trends and Insights

 

The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the October 31, 2019 status of brand negotiations.  Highlights since the last update include:

  • 4 products completed CADTH review, for a total of 7 files under consideration;
  • 2 products initiated pCPA negotiations, for a total of 42 active negotiations;
  • 6 negotiations completed for a total of 282 completed negotiations;
  • 2 negotiation closed, for a total of 47 closed negotiations; and
  • 1 file closed without negotiations, for a total of 70 declined negotiations.

 

 Files Under pCPA Consideration

 

4 new drug products received a CDEC recommendation or pERC notification to implement in October 2019, for a total of approximately 7 products under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Recommendation
Pomalyst Pomalidomide Celgene Multiple Myeloma (second-line or beyond) Conditional
Keytruda Pembrolizumab Merck Metastatic Urothelial Carcinoma (First Line)
Do not reimburse
Botox OnabotulinumtoxinA Allergan Migraine, Chronic Conditional
Xultophy Insulin degludec + liraglutide Novo Nordisk Diabetes mellitus, type 2 Conditional

Note: The Request for Advice for Fibristal (ulipristal acetate) for uterine fibroids (signs and symptoms) has been removed from the under-consideration list as it has been addressed at the provincial level, as demonstrated by the listing in Ontario in October 2019.

 

Negotiation Initiation

 

The pCPA initiated 2 new negotiations since the last update, for a total of 42 active negotiations.

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Initiate
Dovato Dolutegravir

lamivudine

ViiV Healthcare HIV-1 infection September 30, 2019 15 days
Mezera Mesalazine Avir Pharma Ulcerative colitis N/A N/A

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

Signals Decoded:
 
The average time under pCPA Consideration continues to remain below 30 days for the fourth consecutive month, meeting pCPA’s targeted completion time of ≤ 40 business days (from HTA recommendation). In addition, there have been no files under consideration for a period of longer than 6 months since May 2019.The number of active negotiations at 42 is at the lowest number since March 2018.

 

 


 

Completed

 

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Delstrigo Doravirine/

lamuvidine/

tenofovir disoproxil fumarate

Merck HIV Infection June 2019 122 days
Pifeltro Doravirine Merck HIV Infection June 2019 122 days
Venclexta

Rituximab

Venetoclax/

rituximab

AbbVie Chronic lymphocytic leukemia June 2019 122 days
Ogivri Trastuzumab BGP Pharma early breast cancer, metastatic breast cancer, and gastric cancer May 2019 153 days
Trazimera Trastuzumab Pfizer early breast cancer, metastatic breast cancer, and gastric cancer May 2019 153 days
Opdivo Nivolumab Bristol Myers Squibb Classic Hodgkin’s Lymphoma October 2018 365 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

Closed

 

Brand Name Generic Name Manufacturer Indication Initiation Duration*
Herceptin SC Trastuzumab Hoffman-LaRoche Breast Cancer January 2019 273 days
Praluent Alirocumab Sanofi-Aventis prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) August 2018 426 days

 


 

Not Negotiated

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Decision*
Lonsurf Trifluridine and Tipiracil Taiho Pharma Metastatic Colorectal Cancer September 16, 2019 29 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

Signals Decoded:
 
The number of long-standing active negotiations (> 12 months) has decreased by 50% since early 2019, now down to only 3 files with the closing of Praluent which was active for over one year. This month shows some movement on trastuzumab biosimilars and Herceptin SC, with 2 of the 3 trastuzumab biosimilars reaching a LOI, and the negotiation for Herceptin SC closing without a LOI. Opdivo has completed its sixth successful pCPA negotiation. The workload at pCPA appears to have stabilized over 2019 with pCPA adjudicating between 5 and 10 files per month.

 

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
RWE and OBA Working Group 2019 Findings & Executive Summary
NEXT POST →
Update on the CanREValue Collaboration

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
The workload at pCPA appears to have stabilized over 2019